Screening for Social Determinants of Health to Improve Care for Pediatric Sickle Cell Disease
Approximately two-thirds of patients who completed a screening questionnaire reported having at least 1 unmet socioeconomic need.
Approximately two-thirds of patients who completed a screening questionnaire reported having at least 1 unmet socioeconomic need.
Nearly two-thirds of ischemic strokes occurred in patients who had not properly completed the STOP protocol.
Depressive symptoms, spirituality, and missed clinic appointments were all found to correlate with hospital admission in sickle cell disease.
The primary end point was time to readiness for discharge, defined as the difference between the readiness-for-discharge date and time and the start date and time of the first infusion of study drug.
Priority Review shortens the FDA review time from 10 months to 6 months
Patients presenting at emergency departments were nearly 4 times as likely to be admitted to a hospital as patients presenting at a day hospital.
Young patients with sickle cell disease underwent dosing schedules guided by analysis of pharmacokinetic data using a population pharmacokinetic model.
Voxelotor may be a safe and efficacious treatment for sickle cell disease, especially at a dosage of 1500 mg/d.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
A multidisciplinary intervention strategy led to a 61% decrease in hospital stay duration for patients with sickle cell disease and vaso-occlusive pain.